ABSTRACT
Purpose: To provide data of the
incidence and management of common urological
malignancies in renal
transplant recipients . Materials and
Methods: We conducted a retrospective
analysis of a prospective database from August 1967 to August 2015. A descriptive
analysis of the sample was performed.
Results: Among 1256 consecutive RTR a total of 88
patients developed
malignancies (7%). There were 18 genitourinary
tumors in the 16
patients (20.45 % of all
malignant neoplasms ),
incidence of 1.27%. The most common
neoplasm encounter was
renal cancer (38.8%), followed by urothelial
carcinoma (33.3%). Median follow-up of
transplantation was 197 months (R, 36-336). Mean
time from RT to
cancer diagnosis 89±70 months (R, 12-276). CsA and AZA was the most common
immunosuppression regimen in 68.75%. Mean follow-up after
diagnosis was 103±72 months (R 10-215).
Recurrence free
survival rate of 100%. Overall
survival of 89.5% of the sample; there were two non-related
cancer deaths during follow-up.
Conclusions: The
incidence of
neoplasms in RTR was lower than in other series, with favorable functional and oncologic results
after treatment . This suggests that actions to reduce the
risk of these
malignancies as well as a strict follow-up are mandatory for an early
detection and
treatment .